Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese, Japanese Researchers Publish New Info On Dopamine

This article was originally published in PharmAsia News

Executive Summary

Chinese and Japanese scientists, in separate published studies, have elaborated on the role of dopamine in the brain and its relationship to sleep. Their studies suggest dopamine increases when a person has not had enough sleep, a natural response to the drive to sleep. The amount of the increase in dopamine of sleep-deprived people could be involved in their ability to cope with sleep deprivation. One of the two new studies, at Osaka Bioscience Institute in Japan and the Fudan University in China, showed the drug modafinil used for treating narcolepsy is effective because of the presence of two dopamine-sensitive proteins. The work suggests that instead of being the end point itself, dopamine could be merely a link to other molecules involved in the brain's response to sleep loss. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel